<DOC>
	<DOCNO>NCT01009801</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin , work different way stop growth tumor cell , either kill cell stop dividing . Chemoembolization kill tumor cell carry drug directly tumor block blood flow tumor . Everolimus may stop growth tumor cell block enzymes need cell growth block blood flow tumor . It yet know whether transarterial chemoembolization doxorubicin effective give alone give together everolimus treat patient liver cancer . PURPOSE : This randomized phase I/II trial study side effect best dose everolimus give together transarterial chemoembolization doxorubicin see well work compare give transarterial chemoembolization doxorubicin alone treat patient liver cancer .</brief_summary>
	<brief_title>Transarterial Chemoembolization With Doxorubicin With Without Everolimus Treating Patients With Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine recommend dose everolimus patient hepatocellular carcinoma ( HCC ) treat transarterial chemoembolization doxorubicin-eluting bead ( TACE ) . ( Phase I ) - Determine efficacy tolerability everolimus patient HCC treat TACE compare TACE alone . ( Phase II ) OUTLINE : This multicenter , dose-escalation phase I study follow randomized phase II study . - Phase I : Patients receive oral everolimus daily absence disease progression unacceptable toxicity . Beginning 7 day start everolimus patient undergo transarterial chemoembolization ( TACE ) comprise doxorubicin-eluting bead hepatic artery follow 4 week MRI . If viable tumor find patient undergo another TACE treatment continue every 4 week 5 treatment . - Phase II : Patients stratify accord center , age ( ≤ 60 v &gt; 60 year ) , number lesion ( ≤ 3 v &gt; 3 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral placebo daily 12 month undergo TACE comprise doxorubicin-eluting bead phase I maximum tolerate dose ( MTD ) . - Arm II : Patients receive oral everolimus daily 12 month undergo TACE comprise doxorubicin-eluting bead phase I MTD . In arm , patient receive treatment 12 month absence disease progression unacceptable toxicity . Blood sample collect periodically analysis AFP tumor marker . Patients also complete quality life questionnaire , Health Economic Assessment , EQ5D questionnaires baseline periodically study . After completion study treatment , patient follow day 30 , every 3 month .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically , cytologically , radiologically confirm hepatocellular carcinoma Intermediate stage B ( accord Barcelona Clinic Liver Cancer classification ) ChildPugh score &lt; 8 No tumor involvement &gt; 50 % whole liver No advance stage disease ( i.e. , either portal invasion [ segmental portal obstruction ] extrahepatic spread ) No presence history metastatic disease Candidate transarterial chemoembolization multidisciplinary discussion ( tumor board ) Not active wait list liver transplantation PATIENT CHARACTERISTICS : WHO performance status 01 Hemoglobin ≥ 90 g/L Absolute neutrophil count ≥ 1.5 x 10^9/L Platelet count ≥ 100 x 10^9/L Bilirubin ≤ 1.5 x upper limit normal ( ULN ) ALT ≤ 4 x ULN INR ≤ 2 Creatinine ≤ 1.5 x ULN Not pregnant nursing Fertile patient must use effective contraception 12 month completion study therapy Negative pregnancy test None follow contraindication : Complete portal vein thrombosis Large arterioportal arteriovenous fistula within liver Allergy contrast medium Contraindication hepatic artery catheterization , severe peripheral vascular disease preclude catheterization No active heart disease , include follow : NYHA class IIIV congestive heart failure Active coronary artery disease ( myocardial infarction &gt; 6 month prior trial entry allow ) Cardiac arrhythmia require antiarrhythmic therapy ( betablockers digoxin permit ) Uncontrolled hypertension No hypertension , define systolic blood pressure ( BP ) &gt; 150 mm Hg diastolic BP &gt; 90 mm Hg despite optimal medical management No thrombotic embolic event within past 6 month include follow : Cerebrovascular accident ( include transient ischemic attack ) Pulmonary embolism Deep vein thrombosis No serious nonhealing wound , include wound heal secondary intention , acute nonhealing ulcer , bone fracture within 3 month fracture No evidence bleed diathesis No history hemoptysis No clinically serious infection &gt; grade 2 ( NCI CTCAE Version 3.0 ) except HBV HCV infection No known HIV infection No CTCAE acute adverse event grade &gt; 2 prior TACE therapy No prior concurrent malignancy distinct primary site histology HCC , except carcinoma situ cervix , treat nonmelanoma skin cancer , superficial bladder tumor ( Ta , Tis , T1 ) , cancer curatively treat &gt; 3 year prior entry No psychiatric disorder preclude understanding information trial related topic , give informed consent , fill QL form , interfere compliance oral drug intake No serious underlie medical condition , judgment investigator , could impair ability patient participate trial ( e.g. , active autoimmune disease , uncontrolled diabetes ) No know hypersensitivity trial drug hypersensitivity component trial drug No contraindication MRI ( e.g. , pacemaker ) No organ allograft No known impairment swallow would preclude administration everolimus Completed baseline quality life , BLHEA , EQ5D questionnaires ( Phase II ) Able comply geographic proximity allow proper stag followup PRIOR CONCURRENT THERAPY : At least 4 week since prior transarterial embolization/chemoembolization [ limit 5 treatment ] , radiofrequency ablation , cryoablation , radiation therapy percutaneous ethanol injection At least 4 week since prior sorafenib At least 30 day since treatment experimental drug anticancer therapy , treatment another clinical trial At least 30 day since use biologic response modifier ( e.g. , GCSF hematopoietic growth factor ) More 4 week since prior concurrent major surgery More 3 week since prior concurrent radiotherapy Concurrent erythropoietin allow provide dose adjustment undertaken within 1 month prior trial trial No concurrent anticancer drug ( e.g. , bevacizumab , drug target VEGF VEGF receptor ) No concurrent investigational drug No concurrent know strong CYP3A4 inhibitor ( e.g. , ketoconazole , fluconazole , itraconazole , voriconazole , erythromycin , clarithromycin , diltiazem , verapamil , protease inhibitor ) No concurrent know strong CYP3A4 inducer ( e.g. , carbamazepine , continuous treatment dexamethasone [ &gt; 2 mg/day &gt; 7 day ] , phenobarbital , phenytoin , rifampicin , St. John 's wort ) No concurrent grapefruit , grapefruit juice , product contain bitter orange No concurrent systemic corticosteroid ( e.g. , &gt; 1 mg/kg prednisolone ) 2 week No concurrent angiotensin convert enzyme inhibitor ( ACEI )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>localize resectable adult primary liver cancer</keyword>
</DOC>